Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance in formulations, particularly in the US and European markets. However, ARV revenues declined, and API revenues saw a marginal dip.